-
公开(公告)号:PL2264009T3
公开(公告)日:2019-07-31
申请号:PL09721163
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P19/00 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
-
公开(公告)号:ES2718813T3
公开(公告)日:2019-07-04
申请号:ES09721163
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P19/00 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
-
公开(公告)号:AU2009224329B2
公开(公告)日:2013-11-07
申请号:AU2009224329
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: TOKUNAGA YASUNORI , IWAMURA RYO , TANAKA MASAYUKI , SHIGETOMI MANABU , FUJIWARA HIROSHI , OKANARI EIJI , KATSUBE TETSUSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
Abstract: Disclosed is a novel pyridylaminoacetic acid compound represented by general formula (1) [wherein R
-
公开(公告)号:AU2007205452B2
公开(公告)日:2012-04-12
申请号:AU2007205452
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: OKUDO MAKOTO , SHIGETOMI MANABU , KANDA TOMOKO , HAGIHARA MASAHIKO , NAKANISHI TAKAYUKI , KATSUBE TETSUSHI , IWASE NORIAKI , TANAKA MASAYUKI
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00 , A61P31/00 , A61P43/00
Abstract: Disclosed is a pyrrolopyridazinone compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof. (1) In the formula, R represents an alkyl group or the like; R represents a cycloalkyl group or the like; R represents a hydrogen atom or the like; and R represents a hydrogen atom, a halogen atom or the like.
-
公开(公告)号:AT548369T
公开(公告)日:2012-03-15
申请号:AT07706860
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: HAGIHARA MASAHIKO , TANAKA MASAYUKI , KATSUBE TETSUSHI , OKUDO MAKOTO , IWASE NORIAKI , SHIGETOMI MANABU , KANDA TOMOKO , NAKANISHI TAKAYUKI
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00
Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group -O-R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), "C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group", an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or "C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group", Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl) C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:DK2264009T3
公开(公告)日:2019-04-15
申请号:DK09721163
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P19/00 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
-
公开(公告)号:CA2718393C
公开(公告)日:2015-06-16
申请号:CA2718393
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
Abstract: The present invention provides a pyridylaminoacetic acid compound represented by the following formula (1): (see formula 1) (wherein R1, R2, R3, Y and Z are as defmed in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.
-
公开(公告)号:AU2009224329A1
公开(公告)日:2009-09-17
申请号:AU2009224329
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: TOKUNAGA YASUNORI , FUJIWARA HIROSHI , TANAKA MASAYUKI , KATSUBE TETSUSHI , IWAMURA RYO , SHIGETOMI MANABU , OKANARI EIJI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
Abstract: The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R 1 , R 2 , R 3 , Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.
-
公开(公告)号:AU2007205452A2
公开(公告)日:2008-10-30
申请号:AU2007205452
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: OKUDO MAKOTO , SHIGETOMI MANABU , KANDA TOMOKO , HAGIHARA MASAHIKO , NAKANISHI TAKAYUKI , KATSUBE TETSUSHI , IWASE NORIAKI , TANAKA MASAYUKI
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00 , A61P31/00 , A61P43/00
Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group -O-R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), "C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group", an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or "C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group", Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl) C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:AU8461898A
公开(公告)日:1999-02-22
申请号:AU8461898
申请日:1998-07-31
Applicant: UBE INDUSTRIES
Inventor: KUROKI YOSHIAKI , UENO HITOSHI , TANAKA MASAYUKI , TAKATA KATSUNORI , MOTOYAMA TAKAHIRO , BABA KOUSUKE
IPC: C07D471/04 , C07D491/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D495/18 , C07D513/18
Abstract: The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.
-
-
-
-
-
-
-
-
-